This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Abivax SA Sponsored ADR (ABVX), Icon (ICLR) and Liquidia Technologies (LQDA)

Tipranks - Tipranks - Tue Jun 23, 6:42AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abivax SA Sponsored ADR (ABVX), Icon (ICLR) and Liquidia Technologies (LQDA).

TipRanks' Prime Week Sale - 70% Off

Abivax SA Sponsored ADR (ABVX)

Truist Financial analyst Gregory Renza maintained a Buy rating on Abivax SA Sponsored ADR today and set a price target of $135.00. The company’s shares closed last Thursday at $99.15.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 15.8% and a 47.2% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Viridian Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Abivax SA Sponsored ADR with a $143.17 average price target, which is a 42.4% upside from current levels. In a report issued on June 15, BTIG also maintained a Buy rating on the stock with a $150.00 price target.

See the top stocks recommended by analysts >>

Icon (ICLR)

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on Icon. The company’s shares closed last Thursday at $146.00.

According to TipRanks.com, Singh ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -10.7% and a 38.1% success rate. Singh covers the Healthcare sector, focusing on stocks such as Ardent Health Partners, Inc., Hinge Health, Inc. Class A, and Fortrea Holdings Inc. ;'>

Currently, the analyst consensus on Icon is a Moderate Buy with an average price target of $147.55, a 1.5% upside from current levels. In a report issued on June 18, TipRanks – xAI also downgraded the stock to Hold with a $154.00 price target.

Liquidia Technologies (LQDA)

In a report released today, Julian Harrison from BTIG maintained a Buy rating on Liquidia Technologies, with a price target of $109.00. The company’s shares closed last Thursday at $71.07.

According to TipRanks.com, Harrison is a top 100 analyst with an average return of 45.8% and a 54.9% success rate. Harrison covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Connect Biopharma Holdings, and Maze Therapeutics, Inc. ;'>

Liquidia Technologies has an analyst consensus of Strong Buy, with a price target consensus of $74.50, implying a 5.8% upside from current levels. In a report issued on June 9, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $72.00 price target.

Read More on ABVX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).